• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Image

Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

  • Published: April 2014
  • Region: Global
  • 314 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Biogen Idec
  • Eli Lilly
  • Hospira
  • Mylan
  • Sanofi
  • MORE

The Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter royalty financing deals.

Comprehensive directory of royalty financing deals since 2007
Royalty financing contract documents
Royalty financing agreement terms
Royalty financing agreement structure
Top royalty financing deals by value
Most active Royalty financing dealmakers

The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter royalty financing partnering deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents READ MORE >

TABLE OF CONTENTS

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in royalty financing dealmaking

2.1. Introduction
2.2. Difference between royalty and revenue financing deals
2.3. Trends in royalty financing deals since 2007
2.4. Reasons for entering into royalty financing partnering deals
2.5 The emergence of royalty asset purchase deals
2.5.1. Primary players in royalty asset purchase deals
2.5.2. Recent royalty asset purchase deals
2.5.3. The role of big pharma in royalty buyback
2.5.4. The future of royalty asset purchase deals

Chapter 3 – Overview of royalty financing structure

3.1. Introduction
3.2. Anatomy of a royalty asset purchase agreement
3.3. Example royalty financing agreements
3.3.1. Case study 1: Xoma – UCB – Orbimed Advisors – August 2010
3.3.2. Case study 2: Dyax – Paul Capital Healthcare – April 2010
3.3.3. Case study 3: Royalty financing: Biocryst Pharmaceuticals –Shionogi– March 2011
3.3.4. Case study 4: Royalty asset: TPG – CV Therapeutics – April 2008

Chapter 4 – Leading royalty financing deals

4.1. Introduction
4.2. Top royalty financing deals by value
4.3. Top revenue financing deals by value
4.4. Most active royalty financing dealmakers

Chapter 5 – Royalty financing contract documents 2007-2014

5.1. Introduction
5.2. Company A-Z
AxoGen
Cowen Healthcare Royalty Partners
CPPIB Credit Investments
NeurogesX
Novo
Ophthotech
PDL BioPharma
Pharmakon Advisors
Pozen
Stereotaxis
Vivus

Chapter 6 – Royalty financing agreement directory 2007-2014

6.1. Introduction
6.2. Company A-Z
6.3. By therapy area

Central Nervous System
Genitourinary
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Psychiatry
Public Health
Respiratory

Appendix 1 – Royalty financing references
Appendix 2 – Resources
Appendix 3 – Deal type definitions
Appendix 4 – Example royalty financing contract document
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Reports
Order Form – Therapy Reports
Order Form – Reports

TABLE OF FIGURES

Figure 1: Definition of royalty assets
Figure 2: Trends in royalty financing deal announcements, 2007-2014
Figure 3: Trends in revenue financing or ‘synthetic royalty' deal announcements, 2007-2014
Figure 4: Leading royalty asset investors
Figure 5: Recent royalty asset purchase agreements
Figure 6: Components of the royalty asset purchase deal structure
Figure 7: Top royalty financing deals by value since 2007
Figure 8: Top revenue financing deals by value since 2007
Figure 9: Most active royalty financing dealmakers 2007-2014
Figure 10: Online partnering resources
Figure 11: Deal type definitions
Figure 12: Royalty financing agreement for Qutenza – April 2010

Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo
Forest
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Ranbaxy
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB view
Valeant
Warner Chilcott

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos